These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 21777507

  • 1. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
    Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M.
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):107-18. PubMed ID: 21777507
    [Abstract] [Full Text] [Related]

  • 2. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 3. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.
    Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan 15; 35(1):218-26. PubMed ID: 21092748
    [Abstract] [Full Text] [Related]

  • 4. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.
    Clin Schizophr Relat Psychoses; 2014 Jul 15; 8(2):101-9, 109A. PubMed ID: 23446197
    [Abstract] [Full Text] [Related]

  • 5. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA, Sliwa JK, Ma YW, Fu DJ, Alphs L.
    BMC Psychiatry; 2011 May 10; 11():79. PubMed ID: 21569242
    [Abstract] [Full Text] [Related]

  • 6. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L.
    Int Clin Psychopharmacol; 2014 Jan 10; 29(1):45-55. PubMed ID: 24113628
    [Abstract] [Full Text] [Related]

  • 7. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
    Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M.
    Int J Neuropsychopharmacol; 2010 Jun 10; 13(5):635-47. PubMed ID: 19941696
    [Abstract] [Full Text] [Related]

  • 8. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G.
    BMC Psychiatry; 2012 Mar 28; 12():26. PubMed ID: 22455454
    [Abstract] [Full Text] [Related]

  • 9. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
    Carter NJ.
    Drugs; 2012 May 28; 72(8):1137-60. PubMed ID: 22571444
    [Abstract] [Full Text] [Related]

  • 10. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
    Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM.
    CNS Drugs; 2011 Oct 01; 25(10):829-45. PubMed ID: 21936586
    [Abstract] [Full Text] [Related]

  • 11. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M, Pei H, Savitz A, Nuamah I, Hough D, Alphs L, Gopal S.
    Clin Drug Investig; 2018 Aug 01; 38(8):695-702. PubMed ID: 29882073
    [Abstract] [Full Text] [Related]

  • 12. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M.
    Schizophr Res; 2010 Feb 01; 116(2-3):107-17. PubMed ID: 19959339
    [Abstract] [Full Text] [Related]

  • 13. Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.
    Perry R, Wolberg J, DiCrescento S.
    Am J Health Syst Pharm; 2012 Jan 01; 69(1):40-3. PubMed ID: 22180550
    [Abstract] [Full Text] [Related]

  • 14. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D.
    J Psychopharmacol; 2011 May 01; 25(5):685-97. PubMed ID: 20615933
    [Abstract] [Full Text] [Related]

  • 15. Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
    Alphs L, Bossie CA, Fu DJ, Ma YW, Kern Sliwa J.
    Expert Opin Pharmacother; 2014 May 01; 15(7):1029-42. PubMed ID: 24754314
    [Abstract] [Full Text] [Related]

  • 16. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
    Owen RT.
    Drugs Today (Barc); 2010 Jul 01; 46(7):463-71. PubMed ID: 20683501
    [Abstract] [Full Text] [Related]

  • 17. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
    Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J.
    J Clin Psychopharmacol; 2010 Jun 01; 30(3):235-44. PubMed ID: 20473057
    [Abstract] [Full Text] [Related]

  • 18. Intramuscular paliperidone palmitate.
    Hoy SM, Scott LJ, Keating GM.
    CNS Drugs; 2010 Mar 01; 24(3):227-44. PubMed ID: 20155997
    [Abstract] [Full Text] [Related]

  • 19. Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.
    Alphs L, Gopal S, Karcher K, Kent J, Sliwa JK, Kushner S, Nuamah I, Singh J.
    Curr Drug Saf; 2011 Feb 01; 6(1):43-5. PubMed ID: 21047303
    [Abstract] [Full Text] [Related]

  • 20. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.
    Cleton A, Rossenu S, Crauwels H, Berwaerts J, Hough D, Gopal S, Eerdekens M, Vandebosch A, Remmerie B, De Meulder M, Rosso CM.
    J Clin Pharmacol; 2014 Sep 01; 54(9):1048-57. PubMed ID: 24676998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.